Royalty Pharma plc (RPRX) Shareholders & Insider Trades
Royalty Pharma shareholders at a glance
The largest holder of Royalty Pharma stock is Eaton Vance Management, with 42.9 million shares (9.64% of the company), worth about $2.64 billion as of September 25, 2026. The 10 largest holders together own 44.9%.
In Q2 2026, 666 institutional holdings reports listed 406.0 million shares worth $21.30 billion, up 14.4% in shares from Q1 2026.
Insiders reported 74 transactions in the last two years: 28 sales worth $60.35 million and no purchases. The newest one on file is from May 14, 2026 (Urist Marshall J., Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 14, 2026.
Royalty Pharma plc
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Royalty Pharma shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Eaton Vance Management | 42.9 million | 9.64% | $2.6B |
| Capital Research & Management Co. (International Investors) | 35.3 million | 7.92% | $2.2B |
| Fidelity Management & Research Co. LLC | 24.5 million | 5.50% | $1.5B |
| BlackRock Advisors LLC | 22.1 million | 4.96% | $1.4B |
| R & H Trust Co. Ltd. | 21.4 million | 4.80% | $1.3B |
| State Street Corporation | 12.3 million | 2.77% | $758.0M |
| T. Rowe Price International Ltd. | 11.2 million | 2.51% | $687.0M |
| Swedbank Ab | 10.7 million | 2.41% | $659.0M |
| Baillie Gifford & Co. | 10.0 million | 2.25% | $615.0M |
| Capital Research & Management Co. (World Investors) | 9.5 million | 2.14% | $584.0M |
As of September 25, 2026.
Royalty Pharma institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 666 | 406.0 million | $21.3B |
| Q1 2026 | 606 | 355.0 million | $17.0B |
| Q4 2025 | 556 | 358.0 million | $13.8B |
| Q3 2025 | 509 | 331.0 million | $11.7B |
| Q2 2025 | 479 | 343.0 million | $12.4B |
| Q1 2025 | 475 | 323.0 million | $10.1B |
| Q4 2024 | 432 | 322.0 million | $8.2B |
| Q3 2024 | 409 | 316.0 million | $8.9B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Royalty Pharma insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Urist Marshall J. | May 14, 2026 | Officer | Sale at price 53.06 per share. | $726,137 |
| Norden Gregory | May 14, 2026 | Director | Sale at price 53.00 per share. | $161,385 |
| Legorreta Pablo G | May 6, 2026 | Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Hite Christopher D. | May 6, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Coyne Terrance P | May 6, 2026 | Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Urist Marshall J. | May 6, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Coyne Terrance P | Apr 28, 2026 | Chief Financial Officer | Sale at price 49.78 per share. | $1.7M |
| Coyne Terrance P | Apr 1, 2026 | Chief Financial Officer | Sale at price 48.33 per share. | $1.7M |
| Bassler Bonnie L | Mar 31, 2026 | Director | Stock Award(Grant) at price 45.98 per share. | $37,471 |
| Coyne Terrance P | Mar 23, 2026 | Chief Financial Officer | Sale at price 45.53 per share. | $1.6M |
| Coyne Terrance P | Mar 2, 2026 | Chief Financial Officer | Sale at price 46.67 - 47.01 per share. | $1.6M |
| Coyne Terrance P | Feb 23, 2026 | Chief Financial Officer | Sale at price 45.32 per share. | $1.6M |
Newest 12 of 74 insider transactions in the last two years.
Questions and answers
Who owns the most Royalty Pharma stock?
Eaton Vance Management, with 9.64% of the company (as of September 25, 2026). Next: Capital Research & Management Co. (International Investors) (7.92%) and Fidelity Management & Research Co. LLC (5.50%).
How many institutions own Royalty Pharma stock?
666 institutional holdings reports listed Royalty Pharma shares in Q2 2026, 406.0 million shares in all worth $21.30 billion.
Are Royalty Pharma insiders buying or selling the stock?
In the last two years insiders reported 28 sales and no purchases (74 transactions in all); the newest on file is from May 14, 2026.
